Randomized, Placebo-Controlled, Phase II Trial Examining Ustekinumab for Prevention of Graft Vs. Host Disease After Allogeneic Hematopoietic Cell Transplantation
Latest Information Update: 17 Jun 2024
At a glance
- Drugs Ustekinumab (Primary) ; Ustekinumab (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 12 Jun 2024 Planned End Date changed from 31 Mar 2027 to 30 Sep 2027.
- 12 Jun 2024 Planned primary completion date changed from 30 Sep 2025 to 31 Mar 2026.
- 20 Mar 2024 Planned End Date changed from 31 Mar 2026 to 31 Mar 2027.